QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
Positive News Sentiment  
NASDAQ:OMGA

Omega Therapeutics - OMGA Stock Forecast, Price & News

$7.77
+0.01 (+0.13%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$7.52
▼
$7.80
50-Day Range
$4.75
▼
$10.95
52-Week Range
$1.98
▼
$14.31
Volume
22,743 shs
Average Volume
81,997 shs
Market Capitalization
$373.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.75

Omega Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
12.6% Upside
$8.75 Price Target
Short Interest
Bearish
1.84% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$160,000 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.12) to ($2.68) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

765th out of 1,055 stocks

Biological Products, Except Diagnostic Industry

122nd out of 170 stocks

See Top Rated MarketRank™ Stocks Here

OMGA stock logo

About Omega Therapeutics (NASDAQ:OMGA) Stock

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. Its OMEGA Epigenomic Programming platform harnesses the power of epigenetics, as well as the mechanism that controls gene expression and aspect of an organism's life. The company's platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a range without altering native nucleic acid sequences. Its modular and programmable mRNA medicines, and Omega Epigenomic Controllers are designed to target specific epigenomic loci within insulated genomic domains from genome-wide DNA-sequences with single or multiple genes to treat and cure diseases through Precision Genomic Control. The company is advancing a pipeline of development candidates covering a range of disease areas, including oncology, regenerative medicine, multigenic diseases, and select monogenic diseases. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Receive OMGA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omega Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OMGA Stock News Headlines

January 17, 2023 | finance.yahoo.com
Omega Therapeutics to Present Trial-in-Progress Poster for Phase 1/2 MYCHELANGELO™ I Study at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
January 10, 2023 | finance.yahoo.com
Omega Feeders introduces a new cattle feedlot
January 27, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
December 8, 2022 | finance.yahoo.com
KSQ Appoints Mahesh Karande to its Board of Directors
November 28, 2022 | finance.yahoo.com
Wall Street Analysts Think Omega Therapeutics, Inc. (OMGA) Could Surge 136%: Read This Before Placing a Bet
November 17, 2022 | finance.yahoo.com
Omega Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 15, 2022 | finance.yahoo.com
Omega Therapeutics Named One of BioSpace's 2023 Best Places to Work
November 11, 2022 | finance.yahoo.com
Wall Street Analysts Believe Omega Therapeutics, Inc. (OMGA) Could Rally 229%: Here's is How to Trade
January 27, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
November 10, 2022 | finance.yahoo.com
Shareholders in Omega Therapeutics (NASDAQ:OMGA) have lost 79%, as stock drops 13% this past week
November 8, 2022 | finance.yahoo.com
Omega Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
November 3, 2022 | finance.yahoo.com
Omega Therapeutics to Participate in the Jefferies London Healthcare Conference
November 2, 2022 | finance.yahoo.com
Omega Therapeutics Receives Orphan Drug Designation for OTX-2002 for the Treatment of Hepatocellular Carcinoma
October 27, 2022 | finance.yahoo.com
Omega Therapeutics Announces First Patient Dosed in Landmark MYCHELANGELO™ I Trial of OTX-2002 in Hepatocellular Carcinoma and Other Solid Tumor Types Associated with the MYC Oncogene
September 26, 2022 | finance.yahoo.com
Omega Therapeutics to Participate in Two Upcoming Investor Conferences
September 6, 2022 | finance.yahoo.com
Omega Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 1, 2022 | finance.yahoo.com
Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors
August 4, 2022 | finance.yahoo.com
Omega Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
August 3, 2022 | finance.yahoo.com
Omega Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference
July 15, 2022 | seekingalpha.com
Omega Therapeutics gets FDA nod to start liver cancer trial of lead drug OTX-2002
July 14, 2022 | finance.yahoo.com
Omega Therapeutics Announces FDA Clearance of IND Application for OTX-2002, First Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma
July 11, 2022 | finance.yahoo.com
Omega Therapeutics, Inc. (NASDAQ:OMGA) is up 28%, but insiders still continue to see a loss of US$692k on their US$952k investment
June 30, 2022 | finance.yahoo.com
Omega Therapeutics Touts Encouraging Preclinical Data In Liver Cancer Animal Models
June 30, 2022 | finance.yahoo.com
Omega Therapeutics Presents New Preclinical Data Supporting the First Epigenomic Controller, OTX-2002, as a Potential Therapeutic Approach in Hepatocellular Carcinoma at the ESMO 2022 World Congress on Gastrointestinal Cancer
June 23, 2022 | finance.yahoo.com
Omega Therapeutics to Present New Preclinical Data for the First Epigenomic Controller, OTX-2002, for Hepatocellular Carcinoma at the European Society of Medical Oncology's 2022 World Congress on Gastrointestinal Cancer
June 15, 2022 | msn.com
Omega Therapeutics Submits IND For Liver Cancer Candidate
June 15, 2022 | finance.yahoo.com
Omega Therapeutics Announces Submission of Investigational New Drug Application for OTX-2002, an Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma
See More Headlines
Receive OMGA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omega Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OMGA Company Calendar

Last Earnings
11/08/2022
Today
1/27/2023
Next Earnings (Estimated)
3/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OMGA
CUSIP
N/A
CIK
1850838
Web
www.omegatherapeutics.com
Phone
617-949-4360
Fax
N/A
Employees
79
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.75
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+12.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.94)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-68,280,000.00
Net Margins
-6,252.80%
Pretax Margin
-6,253.54%
Return on Equity
-55.11%
Return on Assets
-45.58%

Debt

Debt-to-Equity Ratio
0.15
Current Ratio
10.96
Quick Ratio
10.96

Sales & Book Value

Annual Sales
$140,000.00
Price / Sales
2,666.72
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.20 per share
Price / Book
1.85

Miscellaneous

Outstanding Shares
48,049,000
Free Float
19,220,000
Market Cap
$373.34 million
Optionable
Not Optionable
Beta
0.59

Key Executives

  • Dr. Noubar B. Afeyan Ph.D. (Age 59)
    Co-Founder & Chairman
    Comp: $36.42k
  • Mr. Mahesh Karande (Age 49)
    Pres, CEO & Board Director
    Comp: $1.04M
  • Dr. Thomas McCauley (Age 53)
    Chief Scientific Officer
    Comp: $588.5k
  • Mr. Joshua Reed M.B.A. (Age 49)
    Chief Financial Officer
  • Dr. Sivakesava Sakhamuri Ph.D.
    Sr. VP and Head of Technical Operations & Quality
  • Ms. Ling Zeng Esq. (Age 53)
    J.D., Chief Legal & Admin. Officer and Sec.
  • Mr. Kevin McManus (Age 54)
    Chief HR Officer
  • Ms. Barbara Y. Chan (Age 58)
    Sr. VP of Fin.
  • Mr. Charles O'Donnell Ph.D.
    VP and Head of Computational Genomics & Data Sciences
  • Dr. Yan Moore M.D. (Age 55)
    Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













OMGA Stock - Frequently Asked Questions

Should I buy or sell Omega Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Omega Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OMGA shares.
View OMGA analyst ratings or view top-rated stocks.

What is Omega Therapeutics' stock price forecast for 2023?

4 analysts have issued twelve-month price targets for Omega Therapeutics' shares. Their OMGA share price forecasts range from $4.00 to $12.00. On average, they expect the company's stock price to reach $8.75 in the next year. This suggests a possible upside of 12.6% from the stock's current price.
View analysts price targets for OMGA or view top-rated stocks among Wall Street analysts.

How have OMGA shares performed in 2023?

Omega Therapeutics' stock was trading at $5.71 at the start of the year. Since then, OMGA stock has increased by 36.1% and is now trading at $7.77.
View the best growth stocks for 2023 here.

When is Omega Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our OMGA earnings forecast.

How were Omega Therapeutics' earnings last quarter?

Omega Therapeutics, Inc. (NASDAQ:OMGA) announced its earnings results on Tuesday, November, 8th. The company reported ($0.54) EPS for the quarter, topping analysts' consensus estimates of ($0.63) by $0.09. The firm earned $0.60 million during the quarter. Omega Therapeutics had a negative trailing twelve-month return on equity of 55.11% and a negative net margin of 6,252.80%.

When did Omega Therapeutics IPO?

(OMGA) raised $126 million in an initial public offering on Friday, July 30th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share.

What is Omega Therapeutics' stock symbol?

Omega Therapeutics trades on the NASDAQ under the ticker symbol "OMGA."

How do I buy shares of Omega Therapeutics?

Shares of OMGA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Omega Therapeutics' stock price today?

One share of OMGA stock can currently be purchased for approximately $7.77.

How much money does Omega Therapeutics make?

Omega Therapeutics (NASDAQ:OMGA) has a market capitalization of $373.34 million and generates $140,000.00 in revenue each year. The company earns $-68,280,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis.

How can I contact Omega Therapeutics?

Omega Therapeutics' mailing address is 20 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The official website for the company is www.omegatherapeutics.com. The company can be reached via phone at 617-949-4360 or via email at argotomega@argotpartners.com.

This page (NASDAQ:OMGA) was last updated on 1/27/2023 by MarketBeat.com Staff